Abstract:Background Whether exercise provokes sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM) is uncertain. Current European guidelines recommend against high-intensity exercise in individuals with high SCD risk or obstructive physiology. Purpose We investigated the factors associated with exercise-related SCD in HCM. Methods We retrospectively analyzed of 2,844 consecutive patients with HCM who underwent evaluation between 2005 and 2023 at a high-volume tertiary center. SCD events were defined as a composite of aborted SCD, appropriate implantable cardioverter-defibrillator (ICD) shock, and SCD. Among 80 first SCD events (2.8%), 75 events had a description of the physical activity at the time of the event. Patients were classified into two groups according to physical activity level at the time of the SCD event. Group 1 included patients with high-intensity exercise-related SCD events, defined as happening during or immediately after high-intensity exercise or physical activity, while Group 2 included patients with SCD events happening at rest or during light or moderate physical activity. Results The 75 first SCD events included 44 aborted SCD, 22 appropriate ICD shocks, and 9 SCD. Median age at SCD event was 54 (IQR 39.5–62.5) years and 60 (80%) were men. Patients in Group 1 (n=14) were younger than patients in Group 2 (n=61) (23.5 [IQR 16–48] vs. 55 [IQR 44–64] years, p<0.001), and most patients in group 1 (92.9%) were under the age of 60 years. Patients in Group 1 had slightly smaller left ventricular (LV) end-diastolic dimension and had higher ESC SCD risk scores (3.6 [IQR 2.5–6.7] vs. 2.4 [IQR 1.7–4.8], p=0.044) than patients in Group 2; however, there were no significant differences in the proportion of high-risk patients (28.6% vs. 14.8%, p=0.396) or patients with AHA major SCD risk factors (57.1% vs. 55.7%, p=0.999). Otherwise, there were no significant differences in the presence of obstructive physiology, apical HCM, and apical aneurysm, LV systolic and diastolic function, and comorbidities between the two groups. Furthermore, of the 29 patients who underwent genetic testing, there was no difference in the proportion of patients with pathogenic sarcomeric variants according to exercise-related SCD (50.0% vs. 65.2%, p=0.683). To note, there was a non-significant tendency towards higher proportion of thin filament variants in Group 1 than Group 2 among those with pathogenic sarcomeric variants (100% [3/3] vs 26.7% [4/15], p=0.084). Conclusions Most high-intensity exercise-related SCD events happened under the age of 60. The ESC SCD risk score was higher in patients with high-intensity exercise-related SCD events, although the SCD risk categories or AHA risk factors could not discriminate patients at higher risk of events. These results suggest that exercise recommendations should not be based on SCD risk category, presence of obstruction, or degree of LV hypertrophy.

Hypertrophic cardiomyopathy and competitive sports: let 'em play?

Vigorous exercise and sports participation in individuals with hypertrophic cardiomyopathy

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know

Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy

Evolving spectrum of arrhythmogenic cardiomyopathy: Implications for Sports Cardiology

Shifting paradigms in hypertrophic cardiomyopathy: the role of exercise in disease management

Contemporary review on pediatric hypertrophic cardiomyopathy: insights into detection and management

Redefining Management in Hypertrophic Cardiomyopathy: The Role and Challenges of Exercise Rehabilitation

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

High-intensity exercise-related sudden cardiac death in hypertrophy cardiomyopathy

Advances in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

Abstract 12668: Prevalence of Phenotypic Hypertrophic Cardiomyopathy Among Students Referred for Sport Pre-Participation Cardiovascular Screening

Cardiovascular Risks to Young Persons on the Athletic Field

Medical Treatment Strategies for Hypertrophic Cardiomyopathy

The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment

Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies

Sudden Cardiac Death in Young Athletes

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review

An overview of the treatments for hypertrophic cardiomyopathy